Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs AR-201 (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- Sponsors Aimmune Therapeutics
- 21 Aug 2019 According to an Aimmune Therapeutics media release, the company announced that it has randomized its first patient in this study.
- 08 Aug 2019 According to an Aimmune Therapeutics media release, enrollment in this trial is expected to complete in mid-2020.
- 08 Aug 2019 Status changed from planning to recruiting, according to an Aimmune Therapeutics media release.